His primary scientific interests are in Prostate cancer, Prostate, Surgery, Internal medicine and Prostatectomy. His Prostate cancer research is multidisciplinary, incorporating elements of Randomized controlled trial and Urology. His Prostate research is multidisciplinary, incorporating perspectives in Radiation therapy, Biopsy, Incidence, Pathology and Survival analysis.
Specifically, his work in Surgery is concerned with the study of Stage. His research integrates issues of Patient satisfaction and Oncology in his study of Internal medicine. His studies deal with areas such as Prostvac and Chills as well as Sipuleucel-T.
His scientific interests lie mostly in Prostate cancer, Internal medicine, Prostate, Oncology and Surgery. The Prostate cancer study combines topics in areas such as Gynecology and Urology. His research in the fields of Sipuleucel-T, Androgen and Randomized controlled trial overlaps with other disciplines such as In patient.
Paul F. Schellhammer interconnects Biopsy, Carcinoma, Pathology, Radiation therapy and Adenocarcinoma in the investigation of issues within Prostate. His Oncology research incorporates themes from Clinical trial, Disease and Immunotherapy. His studies in Surgery integrate themes in fields like Cystectomy, Quality of life, Radiology and Incidence.
Prostate cancer, Internal medicine, Oncology, Urology and Sipuleucel-T are his primary areas of study. Paul F. Schellhammer combines subjects such as Quality of life, Surgery and Prostate with his study of Prostate cancer. His work is dedicated to discovering how Surgery, Androgen suppression are connected with Clinical endpoint and other disciplines.
His Prostate study integrates concerns from other disciplines, such as Biopsy, Radiology and Penis. His Oncology research integrates issues from Antiandrogens, Quartile, Castration resistant, Gynecology and Radiation therapy. Paul F. Schellhammer has included themes like Immunotherapy, Asymptomatic, Proportional hazards model and Hazard ratio in his Sipuleucel-T study.
His main research concerns Prostate cancer, Internal medicine, Urology, Oncology and Surgery. His Prostate cancer research incorporates elements of Androgen and Hazard ratio. He focuses mostly in the field of Hazard ratio, narrowing it down to topics relating to Proportional hazards model and, in certain cases, Prostate-specific antigen.
Paul F. Schellhammer works mostly in the field of Surgery, limiting it down to topics relating to Androgen suppression and, in certain cases, Clinical endpoint, Radiation therapy and Randomized controlled trial. The concepts of his Sipuleucel-T study are interwoven with issues in Chills and Immunotherapy. His work deals with themes such as Prostvac, Gastroenterology and Docetaxel, which intersect with Chills.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W. Kantoff;Celestia S. Higano;Neal D. Shore;E. Roy Berger.
The New England Journal of Medicine (2010)
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
Mack Roach;Gerald Hanks;Howard Thames;Paul Schellhammer.
International Journal of Radiation Oncology Biology Physics (2006)
Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer
Eric J. Small;Paul F. Schellhammer;Celestia S. Higano;Charles H. Redfern.
Journal of Clinical Oncology (2006)
Consensus statement: Guidelines for PSA following radiation therapy
James D. Cox;David J. Grignon;Richard S. Kaplan;James T. Parsons.
International Journal of Radiation Oncology Biology Physics (1997)
Serum Protein Fingerprinting Coupled with a Pattern-matching Algorithm Distinguishes Prostate Cancer from Benign Prostate Hyperplasia and Healthy Men
Bao Ling Adam;Yinsheng Qu;John W. Davis;Michael D. Ward.
Cancer Research (2002)
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with Sipuleucel-T in advanced prostate cancer
Celestia S. Higano;Paul F. Schellhammer;Eric J. Small;Patrick A. Burch.
Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues
George L. Wright;Cara Haley;Mary Lou Beckett;Paul F. Schellhammer.
Urologic Oncology-seminars and Original Investigations (1995)
Development of a Novel Proteomic Approach for the Detection of Transitional Cell Carcinoma of the Bladder in Urine
Antonia Vlahou;Paul F. Schellhammer;Savvas Mendrinos;Keyur Patel.
American Journal of Pathology (2001)
Boosted Decision Tree Analysis of Surface-enhanced Laser Desorption/Ionization Mass Spectral Serum Profiles Discriminates Prostate Cancer from Noncancer Patients
Yinsheng Qu;Bao Ling Adam;Yutaka Yasui;Michael D. Ward.
Clinical Chemistry (2002)
Intermittent versus continuous androgen deprivation in prostate cancer.
Maha Hussain;Catherine M. Tangen;Donna L. Berry;Celestia S. Higano.
The New England Journal of Medicine (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: